X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Jubilant to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.
Lead Product(s): NVX-CoV2373,Matrix-M1
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-CoV2373
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Novavax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 29, 2021
Details:
Jubilant HollisterStier LLC, has signed a contract with Eli Lilly and Company (Lilly), for contract manufacturing of Bamlanivimab, that has been granted Emergency Use Authorization by the FDA for emergency use as a treatment of COVID 19.
Lead Product(s): Bamlanivimab
Therapeutic Area: Infections and Infectious Diseases Product Name: LY-CoV555
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
Under the terms of the agreement, Remdesivir will be produced at Saptagir Laboratories' Hyderabad WHO GMP certified sterile drug product manufacturing plant.
Lead Product(s): Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Saptagir Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
